Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging

JK Dyson, QM Anstee, S McPherson - Frontline gastroenterology, 2014 - fg.bmj.com
Non-alcoholic fatty liver disease (NAFLD) is now the commonest cause of abnormal liver
function tests (LFTs) in the UK with approximately a third of the population being affected …

Primary sclerosing cholangitis

JK Dyson, U Beuers, DEJ Jones, AW Lohse, M Hudson - The Lancet, 2018 - thelancet.com
Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterised by
intrahepatic or extrahepatic stricturing, or both, with bile duct fibrosis. Inflammation and …

[HTML][HTML] Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

JK Dyson, MD Rutter - World journal of gastroenterology: WJG, 2012 - ncbi.nlm.nih.gov
The association between inflammatory bowel disease (IBD) and colorectal cancer (CRC)
has been recognised since 1925 and still accounts for 10%-15% of deaths in IBD. IBD …

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

GM Hirschfield, JK Dyson, GJM Alexander… - Gut, 2018 - gut.bmj.com
Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an
autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury …

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

MH Chapman, D Thorburn, GM Hirschfield… - Gut, 2019 - gut.bmj.com
These guidelines on the management of primary sclerosing cholangitis (PSC) were
commissioned by the British Society of Gastroenterology liver section. The guideline writing …

Novel therapeutic targets in primary biliary cirrhosis

JK Dyson, GM Hirschfield, DH Adams… - Nature reviews …, 2015 - nature.com
Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by
progressive cholestasis, biliary fibrosis and eventually cirrhosis. It results in characteristic …

Republished: non-alcoholic fatty liver disease: a practical approach to treatment

JK Dyson, QM Anstee… - Postgraduate medical …, 2015 - academic.oup.com
Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many
developed countries. Between 10% and 30% of patients with NAFLD have non-alcoholic …

The new epidemiology of primary biliary cirrhosis

L Griffiths, JK Dyson, DEJ Jones - Seminars in liver disease, 2014 - thieme-connect.com
Primary biliary cirrhosis (PBC) is an autoimmune cholestatic liver disease. Susceptibility to
PBC probably arises from a combination of genetic and environmental factors. The …

[HTML][HTML] Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use

JK Dyson, J Hutchinson, L Harrison, O Rotimi… - Journal of …, 2016 - Elsevier
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease and
hepatocellular carcinoma. There have been rapid advances in HCV treatment with the …

Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score

VS Hegade, A Khanna, LJ Walker, LL Wong… - Digestive diseases and …, 2016 - Springer
Background Fenofibrate (FF) has been suggested as a second-line agent in primary biliary
cholangitis (PBC) patients who do not achieve adequate biochemical response to …